StageZero Life Sciences Completes $7.2 Million Prospectus Offering

December 04, 2020

StageZero Life Sciences Ltd. (TSX:SZLS) completed an overnight marketed public offering for aggregate gross proceeds of over $7.2 million. The offering was co-led by Echelon Wealth Partners Inc. and Clarus Securities Inc.

StageZero operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. As a specialist in PCR testing for the early identification of cancer through blood, the company is positioned to provide both COVID-19 PCR testing (nasal swab) and blood test analysis (antibody testing) during the pandemic. The company’s full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. The company’s next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for ten cancers from a single sample of blood with high sensitivity and specificity for each cancer.

Wildeboer Dellelce LLP acted for the agents in connection with the offering with a team that consisted of Michael Rennie, Carlye Bellavia, Jessica Sorbara and Nickolas Robelek (corporate/securities) and Katy Pitch (tax).